Valneva SE (VALN) Total Liabilities (2020 - 2026)
Valneva SE's (VALN) quarterly Total Liabilities came in at $345.7 million in Q1 2026, up 7.07% year-on-year from $322.9 million in Q1 2025, and up 1.49% quarter-over-quarter from $340.7 million in Q4 2025.
Valneva SE (VALN) Total Liabilities (2020 - 2026) Analysis & Trends
Valneva SE has disclosed Total Liabilities across 7 years of filings, most recently posting $345.7 million for Q1 2026.
- Total Liabilities for Q1 2026 came in at $345.7 million, up 7.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $345.7 million (up 7.07% YoY), and the FY2025 annual result was $340.7 million, changed 0.01% from the prior year.
- Total Liabilities came in at $345.7 million for Q1 2026 at Valneva SE, up from $340.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $706.3 million in Q1 2022 to a low of $322.9 million in Q1 2025.
- The 5-year median for Total Liabilities is $348.1 million (2025), against an average of $405.4 million.
- Peak annual rise in Total Liabilities reached 238.66% in 2022, while the deepest fall reached 44.63% in 2022.
- Valneva SE's Total Liabilities stood at $409.7 million in 2022, then declined by 12.86% to $357.0 million in 2023, then decreased by 4.58% to $340.6 million in 2024, then increased by 0.01% to $340.7 million in 2025, then climbed by 1.49% to $345.7 million in 2026.
- The last three Total Liabilities figures came in at $345.7 million (Q1 2026), $340.7 million (Q4 2025), and $348.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1.74 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 15.48 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 731.60 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 19.51 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 10.44 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 943,068.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 7.12 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 137.56 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 345.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 345.74 Mn |
| Dec 31, 2025 | 340.68 Mn |
| Sep 30, 2025 | 348.09 Mn |
| Jun 30, 2025 | 323.96 Mn |
| Mar 31, 2025 | 322.92 Mn |
| Dec 31, 2024 | 340.65 Mn |
| Sep 30, 2024 | 328.53 Mn |
| Jun 30, 2024 | 323.38 Mn |
| Mar 31, 2024 | 340.68 Mn |
| Dec 31, 2023 | 357.01 Mn |
| Sep 30, 2023 | 395.18 Mn |
| Jun 30, 2023 | 383.15 Mn |
| Mar 31, 2023 | 413.47 Mn |
| Dec 31, 2022 | 409.68 Mn |
| Sep 30, 2022 | 537.51 Mn |
| Jun 30, 2022 | 674.22 Mn |
| Mar 31, 2022 | 706.29 Mn |
| Dec 31, 2021 | 739.89 Mn |
| Sep 30, 2021 | -387.64 Mn |
| Dec 31, 2020 | 443.22 Mn |